Halozyme Therapeutics (NASDAQ:HALO) COO Cortney Caudill Sells 4,263 Shares of Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) COO Cortney Caudill sold 4,263 shares of the business’s stock in a transaction that occurred on Saturday, November 1st. The stock was sold at an average price of $65.19, for a total value of $277,904.97. Following the completion of the transaction, the chief operating officer directly owned 12,737 shares in the company, valued at approximately $830,325.03. This represents a 25.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Halozyme Therapeutics Trading Up 3.4%

Shares of HALO opened at $67.35 on Friday. The firm has a market cap of $7.92 billion, a P/E ratio of 14.18, a price-to-earnings-growth ratio of 0.35 and a beta of 0.95. The company has a debt-to-equity ratio of 1.59, a current ratio of 1.59 and a quick ratio of 1.37. Halozyme Therapeutics, Inc. has a 1 year low of $46.26 and a 1 year high of $79.50. The company has a 50 day simple moving average of $67.14 and a two-hundred day simple moving average of $64.90.

Halozyme Therapeutics (NASDAQ:HALO) last released its earnings results on Monday, November 3rd. The biopharmaceutical company reported $1.72 EPS for the quarter, topping the consensus estimate of $1.63 by $0.09. The firm had revenue of $354.26 million for the quarter, compared to the consensus estimate of $339.18 million. Halozyme Therapeutics had a net margin of 47.91% and a return on equity of 156.95%. The company’s quarterly revenue was up 22.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.27 earnings per share. On average, equities analysts expect that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Institutional Trading of Halozyme Therapeutics

A number of institutional investors have recently bought and sold shares of the stock. Root Financial Partners LLC bought a new position in Halozyme Therapeutics during the third quarter valued at $25,000. Larson Financial Group LLC boosted its stake in shares of Halozyme Therapeutics by 3,118.2% during the 3rd quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 343 shares during the period. Richardson Financial Services Inc. boosted its stake in shares of Halozyme Therapeutics by 87.6% during the 3rd quarter. Richardson Financial Services Inc. now owns 424 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 198 shares during the period. Wealth Preservation Advisors LLC bought a new position in Halozyme Therapeutics during the 1st quarter valued at about $32,000. Finally, Newbridge Financial Services Group Inc. purchased a new stake in Halozyme Therapeutics in the 2nd quarter worth about $32,000. 97.79% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently commented on HALO shares. HC Wainwright reissued a “buy” rating and set a $90.00 price target on shares of Halozyme Therapeutics in a research note on Friday. Wall Street Zen cut Halozyme Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Saturday, December 6th. JPMorgan Chase & Co. raised their target price on shares of Halozyme Therapeutics from $63.00 to $65.00 and gave the company a “neutral” rating in a report on Monday, October 27th. Leerink Partnrs raised shares of Halozyme Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, October 14th. Finally, The Goldman Sachs Group reiterated a “sell” rating and set a $56.00 price objective on shares of Halozyme Therapeutics in a research report on Thursday, December 4th. Six equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $75.10.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.